Biogen Inc (BIIB)
217.51
+4.00
(+1.87%)
USD |
NASDAQ |
May 03, 16:00
218.88
+1.37
(+0.63%)
After-Hours: 20:00
Biogen Accounts Receivable (Quarterly): 2.000B for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 2.000B |
December 31, 2023 | 2.10B |
September 30, 2023 | 2.210B |
June 30, 2023 | 2.124B |
March 31, 2023 | 2.028B |
December 31, 2022 | 2.136B |
September 30, 2022 | 1.984B |
June 30, 2022 | 2.004B |
March 31, 2022 | 2.021B |
December 31, 2021 | 1.962B |
September 30, 2021 | 2.123B |
June 30, 2021 | 2.110B |
March 31, 2021 | 2.224B |
December 31, 2020 | 2.327B |
September 30, 2020 | 2.552B |
June 30, 2020 | 2.575B |
March 31, 2020 | 2.604B |
December 31, 2019 | 2.471B |
September 30, 2019 | 2.516B |
June 30, 2019 | 2.517B |
March 31, 2019 | 2.616B |
December 31, 2018 | 2.485B |
September 30, 2018 | 2.526B |
June 30, 2018 | 2.433B |
March 31, 2018 | 2.493B |
Date | Value |
---|---|
December 31, 2017 | 2.320B |
September 30, 2017 | 2.086B |
June 30, 2017 | 2.133B |
March 31, 2017 | 1.826B |
December 31, 2016 | 1.742B |
September 30, 2016 | 1.773B |
June 30, 2016 | 1.627B |
March 31, 2016 | 1.710B |
December 31, 2015 | 1.542B |
September 30, 2015 | 1.328B |
June 30, 2015 | 1.311B |
March 31, 2015 | 1.390B |
December 31, 2014 | 1.292B |
September 30, 2014 | 1.091B |
June 30, 2014 | 1.002B |
March 31, 2014 | 1.018B |
December 31, 2013 | 824.41M |
September 30, 2013 | 891.40M |
June 30, 2013 | 861.46M |
March 31, 2013 | 753.61M |
December 31, 2012 | 686.85M |
September 30, 2012 | 661.52M |
June 30, 2012 | 683.84M |
March 31, 2012 | 684.24M |
December 31, 2011 | 584.60M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
1.962B
Minimum
Dec 2021
2.604B
Maximum
Mar 2020
2.229B
Average
2.130B
Median
Accounts Receivable (Quarterly) Benchmarks
Eli Lilly and Co | 7.886B |
Bristol-Myers Squibb Co | 8.826B |
Gilead Sciences Inc | 4.669B |
AbbVie Inc | 11.95B |
Sage Therapeutics Inc | -- |